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ARTICLE
Heterologous biosynthesis and characterization
of a glycocin from a thermophilic bacterium
Arnoldas Kaunietis 1,2, Andrius Buivydas1, Donaldas J. Čitavičius2 & Oscar P. Kuipers1
The genome of the thermophilic bacterium, Aeribacillus pallidus 8, encodes the bacteriocin
pallidocin. It belongs to the small class of glycocins and is posttranslationally modiﬁed,
containing an S-linked glucose on a speciﬁc Cys residue. In this study, the pallidocin bio-
synthetic machinery is cloned and expressed in Escherichia coli to achieve its full biosynthesis
and modiﬁcation. It targets other thermophilic bacteria with potent activity, demonstrated
by a low minimum inhibitory concentration (MIC) value. Moreover, the characterized
biosynthetic machinery is employed to produce two other glycopeptides Hyp1 and Hyp2.
Pallidocin and Hyp1 exhibit antibacterial activity against closely related thermophilic bacteria
and some Bacillus sp. strains. Thus, heterologous expression of a glycocin biosynthetic gene
cluster including an S-glycosyltransferase provides a good tool for production of hypothetical
glycocins encoded by various bacterial genomes and allows rapid in vivo screening.
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R ibosomally synthesized and posttranslationally modiﬁedpeptides (RiPPs) are produced in all three domains of life.Part of the RiPPs overlap with a group of antibacterial
peptides produced by bacteria, and this group historically is
designated as bacteriocins1–3. They are active against other bac-
teria that are mostly closely related to the producer. These pep-
tides exhibit considerable diversity with respect to their size,
structure, mechanism of action, inhibitory spectrum, immunity
mechanisms, and targeted receptors4. In the era of emergence
of antibiotic-resistant bacteria5, bacteriocins have been suggested
as a potential alternative to antibiotics in clinics and veterinary
settings, but also as food preservatives against spoilage and
pathogenic microorganisms2,6,7.
Thermophilic bacteria have shown a great potential in biofuel
production because of their higher metabolic rate and enzyme
stability at elevated temperatures. Moreover, growth at high
temperature facilitates recovery of volatile products, like ethanol8,
and reduces requirement for cooling. Thermophilic fermentations
are less prone to contaminations by mesophiles, although there
are still risks that bioreactors will be contaminated by other
thermophiles9,10. In addition, contamination by thermophiles is
also a problem in production of dairy products11. This shows
the need of discovery of new natural compounds that have
activity against thermophilic bacteria.
Glycocins are posttranslationally glycosylated bacteriocins. The
sugar moieties are linked to the side chains of either Cys, Ser, or
Thr residues. A glycocin can be regarded as being “glycoactive”
when sugar moieties are essential for the antimicrobial activity12.
Only a few glycocins have been identiﬁed and reported to date:
sublancin 168, produced by Bacillus subtilis13; glycocin F,
produced by Lactobacillus plantarum14; ASM1 (homologous
to glycocin F), produced by Lb. plantarum12,15; enterocin F4-9,
produced by Enterococcus faecalis16 and thurandacin, encoded by
Bacillus thuringiensis and identiﬁed by genomic data mining and
chemo-enzymatical synthesis in vitro16.
The understanding of their mechanism of growth inhibition
of target bacteria is far from complete. It is known that a speciﬁc
phosphoenolpyruvate:sugar phosphotransferase system (PTS)
is a factor affecting glycocin F and sublancin antibacterial
activities12,17 and that sublancin does not affect the integrity
of the cell membrane and acts bacteriocidal12,17. In contrast,
glycocin F and enterocin F4-9 have been reported to be
bacteriostatic14,16.
The synthetic machinery of the best-studied glycocin, sub-
lancin, is encoded by a gene cluster containing sunA, sunS, sunT,
bdbA, and bdbB genes. The precursor peptide, SunA, is modiﬁed
by the S-glycosyltransferase SunS, which forms a very unusual S-
linkage between the Cys residue and glucose. SunA glycosylation
in vitro by SunS has been conﬁrmed by chemo-enzymatical
synthesis of mature sublancin13. Based on the SunT sequence
similarity to bacteriocin ABC- transporters/peptidases, it is
assumed that SunT cleaves the leader sequence and transports the
core peptide to the outside of the cell. Two thiol-disulﬁde oxi-
doreductases, BdbA and BdbB, might be responsible for disulﬁde
bond formation in the peptide18,19. In addition, it has been
conﬁrmed that the same gene cluster encodes the immunity
protein SunI20. A similar genetic organization was found in gene
clusters encoding the putative synthetic machineries of glycocin
F14, thurandacin21 and enterocin F4-916.
To date only two bacteriocins, i.e. geobacillin I and geobacillin
II, produced by the thermophilic bacteria Geobacillus thermo-
denitriﬁcans NG80-2, are well characterized22–24. Other
bacteriocin-like antibacterial compounds from thermophilic
microorganisms have been described in much less detail25–31.
These reasons prompted us to ﬁnd and to study new bacteriocins
of this group. Thus, we have chosen the thermophilic Aeribacillus
pallidus 8 strain that was previously isolated from soil above oil
wells in Lithuania32. Previous studies have shown that this strain
secretes an antibacterial compound that is active against other
thermophilic bacteria. Unfortunately puriﬁcation of this com-
pound and identiﬁcation of its amino acid sequence were not
successful32,33.
In this study we have identiﬁed genes in the genome of
A. pallidus 8 that encode a biosynthetic machinery for a hypo-
thetical bacteriocin (i.e. pallidocin), which belongs to the small
class of glycocins. We also demonstrate the functional expression
of the whole biosynthetic gene cluster of a glycocin in Gram-
negative Escherichia coli, which facilitates further engineering
and mechanistic studies.
Following characterization of pallidocin demonstrated that it
exhibits extremely strong activity against speciﬁc thermophilic
bacteria, such as (Para)Geobacillus sp. and Caldibacillus sp. In
addition, we identiﬁed and synthesized a variety of hypothetical
glycopeptides and determined their properties by employing
heterologous expression system of pallidocin. The characterized
pallidocin S-glycosyltransferase PalS could be used not only for
biosynthesis of hypothetical glycocins, but also for introduction
of unique posttranslational modiﬁcations into other peptides
with the aim to improve their bioactivities. Pallidocin is a good
candidate to prevent bacterial contaminations in industrial
fermentations operating under elevated temperatures.
Previously, full maturation of recombinant glycocins was only
reported in vitro for thurandacin and sublancin. Glycosylation
and leader cleavage were performed enzymatically, followed by
chemical oxidative folding13,21. The in vitro experiments limit the
yield of the ﬁnal product, are time consuming and expensive.
Recently, a system was developed for the heterologous expression
of sublancin in E. coli SHufﬂe T7 Express cells that in vivo
installs the glycosylation and oxidative folding following a single
in vitro step of proteolytic leader cleavage34. The SHufﬂe T7
Express strain expresses the disulﬁde bond isomerase DsbC,
aiding oxidative folding of proteins in the cytoplasm35. Here, we
demonstrate a different in vivo heterologous expression system
to produce completely mature glycocins in E. coli BL21(DE3),
evading the in vitro chemical and enzymatic steps.
Results
Identiﬁcation and heterologous biosynthesis of pallidocin.
The pallidocin producer strain was identiﬁed as A. pallidus 8
(previously referred to as Geobacillus sp. 8 32) by a Genome-to-
Genome Distance Calculator (GGDC) using a digital DNA
−DNA hybridization (dDDH) analysis tool36. The A. pallidus 8
genome37 was processed with the BAGEL4 bioinformatics tool38
for the identiﬁcation of gene clusters for bacteriocins biosynthesis.
An operon coding for a putative glycocin was identiﬁed (Fig. 1a).
It contains ﬁve genes which were named palA, palS, palT, paldbA,
and paldbB. Proteins encoded by these genes display between 38
and 53% sequence similarity with proteins of known functions,
encoded in other bacteria. Based on this analysis we presumed
that palA encodes the 61 amino acid precursor peptide (Fig. 1b),
palS encodes the SunS-like family peptide S-glycosyltransferase,
palT encodes the SunT-like superfamily peptidase/ABC trans-
porter protein, paldbA encodes the thioredoxin-like enzyme, and
paldbB encodes the DsbB-like disulﬁde bond formation protein B.
We decided to try to express this gene cluster in the easy-to-
handle Gram-negative host E. coli. The whole biosynthetic gene
cluster (pal) of the hypothetical glycocin (Fig. 1a), which was
named pallidocin, was ampliﬁed by PCR and cloned into the
expression vector (Supplementary Fig. 1). The pal operon,
starting with the start codon for the PalA, was cloned into the
MCS behind the arabinose promoter and RBS of the vector.
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The expression of the pal genes in the heterologous host E. coli
BL21(DE3) was induced with arabinose. The produced active
antibacterial peptide was puriﬁed from 2L of supernatant
(Supplementary Fig. 2) using liquid chromatography methods.
The yield of the peptide was enough for mass spectrometric (MS)
analysis and initial antibacterial activity screening, but not for
the quantiﬁcation by measuring the absorbance at 280 nm
wavelength.
Structural and functional characterization of pallidocin. The
predicted monoisotopic mass [M+H]+ of the unmodiﬁed pal-
lidocin core peptide is 4061.76. The monoisotopic mass [M+H]
+ of puriﬁed native pallidocin observed by LC-ESI-MS was
4219.79 (Supplementary Fig. 3a). The monoisotopic mass [M+
H]+ of the peptide, after treatment with tris(2-carboxyethyl)
phosphine-hydrochloride (TCEP), was 4223.82 (Supplementary
Fig. 3b). This suggests that the peptide has a posttranslational
modiﬁcation with a mass of +162 and two disulﬁde bonds (−4).
To identify the modiﬁed residue, pallidocin was fragmented with
chymotrypsin and further analyzed by LC-ESI-Q-MS/MS mass
spectrometry (Supplementary Figs. 4-9). This showed that Cys25
of the core peptide has a modiﬁcation with a mass of +162.05,
which might be a hexose moiety. To identify the sugar, pallidocin
was analyzed by GC-MS (Supplementary Fig. 10). The results
demonstrated that the moiety attached to the Cys25 residue
is glucose.
Based on the analysis by the secondary structure prediction
tool PSIPRED39, pallidocin has two α-helices (Fig. 2). Far-UV CD
spectra analysis of mature pallidocin (Supplementary Fig. 11)
revealed that the peptide contains substantial amounts of helical
structure, judging from the pattern of the spectra from 193 to 240
nm. Similar spectra patterns were observed for sublancin34,40,41
and glycocin F14, also. The estimate of the secondary structure
content, made by the method of Raussens et al.42, predicted
predominantly helical structure, with an estimate of 47% helix.
The peptide was also estimated to contain 13% β-turn and 11% β-
sheet structure.
A wide range of temperatures and pHs were applied to evaluate
pallidocin’s stability (Supplementary Table 1). The peptide was
stable at room temperature for 10 days, while after 30 days
it retained 12% of the activity. Fifty percent antibacterial
activity was retained after autoclaving pallidocin at 121 °C for
15 min. Incubation at the pH range 2−10 did not affect
pallidocin’s antibacterial activity, demonstrating its exceptionally
high stability.
Functional assessment of the genes palS and palT. The genes
palS and palT were cloned (Supplementary Fig. 12) and coex-
pressed with palA-his in E. coli BL21(DE3) to determine their
functions. Gene palA was fused with a His7-tag in the C-terminus
(Supplementary Figs. 12 and 13) to facilitate the puriﬁcation of its
product. The highest yield of synthesized peptides was observed
in the insoluble fraction of the cell lysate. Peptides were puriﬁed
from the insoluble fraction, tested for activity and analyzed by
MALDI-TOF-MS to evaluate the presence of modiﬁcations
(Table 1).
As expected, expression of only palA-his resulted in the
synthesis of pre-PalA-His, the precursor peptide with the leader
still attached (Supplementary Fig. 14), and with no antibacterial
activity (Fig. 3). Coexpression of palA-his and palS genes resulted
in the biosynthesis of pre-PalA-His-Glc (the precursor peptide
with the leader attached and a mass increment of 162), which
portrays glucosylation (Supplementary Fig. 15). Notably, this
compound was active against the sensitive thermophilic strain
Parageobacillus genomospecies 1 NUB36187 (Fig. 3). Coexpres-
sion of palA-his with palT resulted in the biosynthesis of the
PalA-His core peptide with a mass corresponding to the
leaderless peptide and this compound lacked antibacterial activity
(Fig. 3). Coexpression of the genes palA-his with palS and palT
resulted in the biosynthesis of a PalA-His-Glc core peptide
(mature pallidocin) with the mass corresponding to the leaderless
peptide with a mass increment of 162, corresponding to
glucosylation (Supplementary Fig. 16). The glucosylated core
peptide had antibacterial activity too (Fig. 3).
The role of disulﬁde bonds on the antibacterial activity. To
conﬁrm the presence and importance of disulﬁde bonds in pal-
lidocin, puriﬁed glycosylated precursor peptide with leader pre-
PalA-His-Glc and leaderless PalA-His-Glc core peptide (mature
pallidocin) were treated with TCEP and iodoacetamide (IAA)
(Supplementary Table 2). These peptides were derived after
coexpression of palA-his with palS or palST. After the treatment,
the masses of pre-PalA-His-Glc and PalA-His-Glc core peptide
measured by MALDI-TOF-MS increased by +234 and +228,
respectively. The expected mass increment for one alkylated Cys























Fig. 1 Gene cluster and precursor peptides of glycocins. a Pallidocin biosynthetic gene cluster (4805 bp) pal identiﬁed by BAGEL4 in A. pallidus 8 genome.
b Alignment of glycocin precursor peptides. Conserved regions are highlighted in green color, Cys forming disulﬁde bonds are underlined in orange,
glycosylated amino acids are underlined in blue. Red dots between amino acids indicate predicted or experimentally determined leader cleavage sites.
Numbers in the end of the sequences indicate the length of peptides in amino acids. PalA pallidocin precursor, SunA sublancin precursor, Hyp putative
glycocin precursor Hyp1, Hyp2 putative glycocin precursor Hyp2, EnfA4-9 enterocin F4-9 precursor, GccF glycocin F precursor
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mass difference (6), which is tolerated as the machine error, it is
clear that the disulﬁde bonds were reduced and all free Cys
residues were alkylated.
Notably, the disruption of disulﬁde bonds resulted in the loss
of antibacterial activity against the indicator strain P. genomos-
pecies 1 NUB36187 (Supplementary Table 2). After treatment
with only IAA, no loss of antibacterial activity and mass
increment was observed (Supplementary Table 2), conﬁrming
that all disulﬁde bonds are present in the pre-PalA-His-Glc and
the PalA-His-Glc core peptide.
In vitro leader peptide cleavage of pallidocin precursor. To
develop a more efﬁcient way for pallidocin production, the genes
his-Xa-palA and palS were coexpressed in E. coli BL21(DE3).
PalA was engineered by adding a His-tag at the N-terminus and a
Factor Xa peptidase cleavage site (IEGR) in front of the core
peptide (Supplementary Fig. 13) for convenient leader removal.
After coexpression, the glycosylated precursor peptide pre-His-
Xa-PalA-Glc was puriﬁed and the leader was cleaved off in vitro
using Factor Xa. The generated leaderless PalA-Glc core peptide







































































































































Fig. 2 Proposed structures of pallidocin, Hyp1 and Hyp2 glycocins based on PSIPRED predictions from the sequence and the known tertiary structure of
sublancin 168 and GccF. α-helical structure highlighted in blue color. Coil structure highlighted in purple. Black dots indicate hydrophobic amino acids.
Orange indicates acidic amino acids, whereas green indicates basic amino acids
Table 1 Results of glycocin precursor genes coexpression with palS and palT
Coexpressed genes palA-his sunA-his hyp1-his hyp2-his enfA4-9-his gccF-his
No coexpression (only precursor
peptide)
NA, NM, NLC NA, NM, NLC NA, NM, NLC NA, NM, NLC NA, NM, NLC NA, NM, NLC
Coexpression with palS +, Glc, NLC +, Glc, NLC +, Glc, NLC NA, Glc, NLC NA, NM, NLC NA, NM, NLC
Coexpression with palT NA, NM, leader
cleaved
NA, NM, NLC NA, NM, NLC NA, NM, NLC NA, NM, NLC NA, NM, NLC
Coexpression with palST +, Glc, leader cleaved +, Glc, NLC +, Glc, NLC NA, Glc, NLC NA, NM, NLC NA, NM, NLC
Glc refers to the peptide’s modiﬁcation with a mass of +162; plus symbol refers to the presence of antibacterial activity of the puriﬁed peptide
NA no activity, NM no modiﬁcations, NLC no leader cleavage, palA-his pallidocin precursor, sunA-his sublancin precursor, hyp1-his putative glycocin precursor Hyp1, hyp2-his putative glycocin precursor
Hyp2, enfA4-9-his enterocin F4-9 precursor, gccF-his glycocin F precursor
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mass spectrometry analysis for mass conﬁrmation (Supplemen-
tary Fig. 17). The yield of synthesized active mature pallidocin
was ~15 μg per 100 mL of bacterial culture. Activities of the
glycosylated precursor peptide with leader and mature pallidocin
were compared by the agar well diffusion assay using P. geno-
mospecies 1 NUB36187 as a sensitive strain (Supplementary
Fig. 18). The assay shows the highest serial twofold dilution of
bacteriocin sample, which still displays antibacterial activity.
Results indicate that pre-His-Xa-PalA-Glc had approximately
500 times lower activity than the mature pallidocin.
Pallidocin alignment with other glycocins. BLAST analysis of
PalA identiﬁed two hypothetical peptides (Hyp1 and Hyp2)
which have low sequence similarity to PalA (Fig. 1b). They were
encoded in Bacillus megaterium BHG1.1 (Hyp1) and Bacillus sp.
JCM19047 (Hyp2) genomes. Hyp1 consists of a 23-residue leader
sequence, a 41-residue core peptide, a 20-residue leader sequence
Hyp2, and a 51-residue core peptide. Each of the peptides Hyp1
and Hyp2 has ﬁve Cys residues in the core sequence.
Genome analyses of B. megaterium BHG1.1 and Bacillus sp.
JCM19047 by the BAGEL4 tool did not ﬁnd any gene clusters
related to bacteriocin biosynthesis. However, BLASTp analysis
of the genomic context of hyp1 revealed a gene cluster coding
for putative glycocin biosynthetic machinery (Fig. 4). Genes in
the cluster alongside the Hyp1 precursor gene encode for:
Hyp1S protein with 50% sequence similarity to SunS-like family
peptide S-glycosyltransferases; Hyp1T protein with 68% sequence
similarity to SunT-like superfamily peptidase domain-containing
ABC transporters; Trx protein with 69% sequence similarity to
thioredoxin-like superfamily proteins and DsbB protein with 74%
sequence similarity to DsbB-like superfamily disulﬁde bond
formation proteins B. Moreover, BLASTp analysis of the genomic
context of hyp2 revealed that a gene cluster may encode for
putative glycocin biosynthetic machinery (Fig. 4). Genes in the
cluster alongside the Hyp2 precursor gene encode the Hyp2S
protein with 42% sequence similarity to SunS-like family peptide
S-glycosyltransferases; Hyp2T protein with 40% sequence simi-
larity to SunT-like superfamily peptidase domain-containing
ABC transporters and the Trx protein with 43% sequence
similarity to thioredoxin-like superfamily proteins. Two putative
glycocin precursors, i.e. Hyp1 and Hyp2, were investigated and
examined further for possible posttranslational modiﬁcations
by the biosynthetic machinery of pallidocin.
Alignment of all glycocins (Fig. 1b) showed that the leader
sequences of SunA, ThuA, PalA, and Hyp1 share motifs of
conserved residues. In contrast, the leader sequences of GccF
and EnfA49 display no signiﬁcant similarities. All glycocins
have a double-glycine type motif (a proteolytic cleavage site at the
end of the leader sequence). GccF and EnfA49 precursors have
leader cleavage sites following the Gly-Gly motif. SunA, ThuA,
and PalA precursors have a Gly-Ser-Gly motif, where the leader
sequence is cleaved between the Ser and second Gly residue. In
case of peptide Hyp2, it has putative leader cleavage site with
motif Gly-Ser-Gly, whereas peptide Hyp1 has Gly-Lys-Gly.
pre-PalA-His-Glc PalA-His-Glc pre-Hyp1-His pre-Hyp1-His-Glc
pre-Hyp2-His pre-Hyp2-His-Glc Hyp2-His Hyp2-His-Glc
Hyp1-His Hyp1-His-Glc pre-SunA-His pre-SunA-His-Glc
pre-PalA-His PalA-His
Fig. 3 Antibacterial activities of synthesized and puriﬁed peptides. The peptides were derived after coexpression of glycocin precursors with PalS/PalT/
PalST proteins in E. coli, subsequent puriﬁcation by Ni2+ afﬁnity chromatography (IMAC) and RP-HPLC. Antibacterial activity was indicated as a clearly
visible inhibition zone of sensitive strain P. genomospecies 1 NUB36187 and assessed by a spot on a lawn assay
hyp1
Hyp1 biosynthetic gene cluster
Hyp2 biosynthetic gene cluster
Precursor
Disulfide bond formation Unknown function
Glycosyltransferase Leader cleavage/ABC type transporter
hyp1S
1000 2000 3000 4000 5000
1000 2000 3000 4000
hyp1T trx dsdB
hyp2 hyp2T trx hyp2S
hyp1U
Fig. 4 The predicted biosynthetic gene clusters of glycocins Hyp1 and Hyp2. Hyp1 biosynthetic gene cluster encoded in the genome of B. megaterium BHG1.1
is 5013 bp in length and encodes for proteins: Hyp1, Hyp1S, Hyp1T, Trx, DsbB, and Hyp1U. The Hyp2 biosynthetic gene cluster encoded in the genome of
Bacillus sp. JCM19047 is 3932 bp in length and encodes for proteins: Hyp2, Hyp2T, Trx, and Hyp2S
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All glycocins characterized to date have ﬁve Cys residues in the
core peptide and form two disulﬁde bonds between them. Hyp1
and Hyp2 core peptides have also ﬁve Cys residues and it is very
probable that they form these bonds too. Early studies and our
current one show that the Cys residue in the conserved region
Gly-Cys-Gly-Gly/Ser of SunA, ThuA and PalA is glucosylated.
This motif is present in Hyp1 and Hyp2 peptides as well and it
suggests that Cys in this region is the target for glycosylation.
The secondary structure prediction tool PSIPRED39 proposes
that two α-helices are present in the Hyp1 and Hyp2 core
peptides as well as in pallidocin. Four out of ﬁve Cys residues
reside in these helical structures of the peptides. Structures of
sublancin 168 and glycocin F elucidated by NMR method have
also two α-helices, which are nested by two disulﬁde bonds43,44
and giving rise to the predicted structures for Hyp1 and Hyp2
(Fig. 2).
Heterologous biosynthesis of hypothetical glycocins. To deter-
mine whether PalS and PalT are able to modify and process
different heterologous glycocin precursors in a heterologous
Gram-negative host, they were coexpressed with genes coding for
glycocin precursor peptides with leaders and His6-tags (Supple-
mentary Figs. 13 and 19), i.e. pre-SunA-His, pre-GccF-His, pre-
EnfA49-His, pre-Hyp1-His and pre-Hyp2-His. As before, the
highest yield of peptides was observed in the insoluble fraction
of cell lysate. After coexpression, the peptides were puriﬁed from
the insoluble fraction and analyzed by mass spectrometry
(Table 1). The analysis could not conﬁrm that PalT cleaved off
the leaders. However, it demonstrated that in addition to pre-
PalA-His, the PalS glycosyltransferase does modify pre-SunA-His
(Supplementary Fig. 20 and 21), pre-Hyp1-His (Supplementary
Figs. 22 and 23), and pre-Hyp2-His (Supplementary Fig. 24
and 25), with a mass of +162 consistently pointing to mono-
glycosylation. The antibacterial activity analysis of the peptides
showed that only pre-SunA-His-Glc and pre-Hyp1-His-Glc
(glycosylated precursors with leaders) but not the pre-Hyp2-
His-Glc were active against indicator strain P. genomospecies
1 NUB36187 (Table 1 and Fig. 3).
We designed the genes core_hyp1-his and core_hyp2-his
encoding the leaderless Hyp1 and Hyp2 core peptides with a
His6-tag sequence at the C-terminus (Supplementary Figs. 13 and
19). As previously, palS was coexpressed with the core_hyp1-his
and core_hyp2-his. The peptides were produced, puriﬁed and
analyzed by mass spectrometry. LC-ESI-MS analysis conﬁrmed
that leaderless Hyp1-His and Hyp2-His core peptides (Supple-
mentary Figs. 26 and 27) were glycosylated. However, only the
Hyp1-His-Glc core peptide showed antibacterial activity against
P. genomospecies 1 NUB36187 (Fig. 3). To conﬁrm the
importance of glycosylation, core_hyp1-his gene was expressed
in E. coli without palS coexpression. The recombinant Hyp1-His
core peptide did not show any antibacterial activity (Fig. 3),
indicating that glycosylation indeed plays a crucial role in the
antimicrobial activity of Hyp1, as well as for pallidocin, pre-
SunA-His-Glc (this work) or mature sublancin13,34 (glucosylated
and oxidatively folded SunA core peptide). In addition, reduced
and alkylated pre-Hyp1-His-Glc (Supplementary Table 3) and
Hyp1-His-Glc core peptides (Supplementary Table 4) lost their
antibacterial activities, conﬁrming that disulﬁde bonds are also
important for glycocin activity.
Antibacterial activity of identiﬁed glycocins. The antibacterial
activity spectrum of puriﬁed pallidocin was tested against a
number of Gram-positive and Gram-negative bacteria using a
spot on lawn assay. Puriﬁed pallidocin exhibited antibacterial
activity against Bacillus cereus ATCC14579, B. megaterium
DSM319 and some thermophilic bacteria: Geobacillus stear-
othermophilus B4109, B4111, B4112, B4114 strains, P. genomos-
pecies 1 NUB36187, Parageobacillus toebii B4110, B4162 strains,
Parageobacillus caldoxylosilyticus B4119 and Caldibacillus debilis
B4165.
The activity spectrum of the synthesized glycocin Hyp1-His-
Glc (glycosylated leaderless core peptide) was partially similar to
the pallidocin spectrum (Supplementary Fig. 28). Glycocin was
active against Geobacillus sp. B4113 and G. stearothermophilus
B4163 strains, but exhibited no activity against G. stearothermo-
philus B4112, P. toebii B4110, P. caldoxylosilyticus B4119 and B.
cereus ATCC14579 strains, in contrast to pallidocin.
Minimum inhibitory concentrations (MICs) were determined
for some pallidocin susceptible strains (Supplementary Tables 5, 6
and 7). In liquid NB medium, the MIC of pallidocin against B.
megaterium DSM319 was 37 nM, P. genomospecies 1 NUB36187
was 2.4 pM (i.e ±10 ng/L), G. stearothermophilus B4114 was 246
pM, Geobacillus toebii B4162 was 493 pM, and P. caldoxylosily-
ticus B4119 was 985 pM. MIC tests showed that Geobacillus spp.
strains used in this assay rapidly acquired resistance for pallidocin
as observed by growing colonies in the halo area or the growth
in some 96-plate wells with pallidocin concentrations higher
than MIC.
Discussion
We identiﬁed and characterized a posttranslationally modiﬁed
bacteriocin (pallidocin). The gene cluster of the pallidocin bio-
synthetic machinery is encoded on the chromosome of the
thermophilic bacterium A. pallidus 8, which is unprecedented.
The characterized bacteriocin belongs to the small class of gly-
cocins and shares genetic and structural similarities with sub-
lancin 16813, glycocin F14, thurandacin21 and enterocin F4-916.
Here, we show that the whole glycocin biosynthetic gene
cluster, derived from a thermophilic bacterium, can be cloned and
functionally expressed in a heterologous host E. coli BL21(DE3).
Surprisingly, mature bacteriocin (glycosylated, oxidatively folded
and leaderless) from Gram-positive bacteria could be synthesized
and secreted by this Gram-negative host. Structural character-
ization of the puriﬁed recombinant pallidocin revealed post-
translational modiﬁcations: glycosylation and two disulﬁde bonds
within two predicted α-helices. These two features appear to be
speciﬁc for the class of glycocins12. Pallidocin has an S-linked
glucose moiety to the Cys25, which is very uncommon among
bacteria. Only a few cases of S-linked glycopeptides have been
described and conﬁrmed to date, i.e. for glycocin F, sublancin 168
and thurandacin13,14,21.
Pallidocin exhibits high stability after exposure to high tem-
peratures and a wide range of pH values. To our knowledge, only
sublancin and enterocin F4-9 have been properly characterized
for their stability. The stability of sublancin is decreased by 50%
after 30 min incubation at 70 °C temperature. Sublancin is not
very stable at acidic conditions; after incubation at pH 2 and 3 for
30 min, it retains only 20 and 40% of its activity, respectively40,
while enterocin F4-9 after incubation at 80 °C for 15 min retains
its full activity only at pH values from 2 to 8. After incubation at
100 °C for 15 min, enterocin F4-9 retains its full activity only at
pH 4. Its activity is completely lost after incubation at 121 °C as
well as at pH 1016. Compared to sublancin and enterocin F4-9,
pallidocin is much more stable at high temperatures. Its activity
decreases 50% only after 15 min incubation at 121 °C and is
completely stable at 90 °C for 3 h. In contrast to sublancin and
enterocin F4-9, pallidocin retains its full activity at acidic and
basic conditions (pH 2−10).
In vitro studies on the glycosylation of the sublancin precursor
showed that S-glycosyltransferase has relaxed substrate speciﬁcity.
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It is able to attach other sugars: xylose, mannose, N-acet-
ylglucosamine or galactose, as well. The native glycopeptide
sublancin puriﬁed from B. subtilis contains glucose13. We do not
know which sugar would be present in native pallidocin if the
peptide was derived from A. pallidus 8. We can assume that
native pallidocin has an S-linked glucose as well, as this sugar was
found in recombinant pallidocin produced by E. coli.
Experiments in which only two or three genes were coex-
pressed revealed that palS codes for an S-glycosyltransferase,
which introduces glucose to the Cys25 residue in pallidocin.
When palA-his was coexpressed with palS and palT, the mature
pallidocin (PalA-His-Glc core peptide) was puriﬁed also. Addi-
tionally, the PalT protein shares sequence similarity to other
bacteriocin ABC transporters, which leads to the conclusion that
PalT has a dual, i.e. peptidase and transport, function.
Oxidative folding of the peptide in the cytoplasm is unlikely.
The formation of structural disulﬁde bonds in E. coli appears to
be strictly segregated according to subcellular compartmentali-
zation45. Because a reducing environment is necessary for enzy-
matic activity of glycosyltransferases13 most probably PalS
glycosylates peptides in the cytoplasm. When the whole gene
cluster pal is expressed, the synthesized glycosylated precursor
peptide should be transported to the periplasm by PalT, where
the oxidative folding could take place. Following the precursor
peptide coexpression with PalS, these bonds could be formed
spontaneously by air oxidation46,47 during peptide extraction
and/or the puriﬁcation process. In case of precursor peptide
coexpression with PalST, disulﬁde bonds in the glycosylated core
peptide could be formed in the periplasm or spontaneously by air
oxidation46,47 during the peptide extraction and puriﬁcation
process.
We applied PalS for possible modiﬁcations of other glycocins
and produced two glycosylated peptides: Hyp1 and Hyp2. PalS
speciﬁcally monoglycosylated a certain group of glycocin
precursors (pre-PalA-His, pre-SunA-His, pre-Hyp1-His, and
pre-Hyp2-His), but it was not able to modify pre-GccF-His
and pre-EnfA4-9-His. Interestingly, the 42%, 50% and 53%
sequence similarities of Hyp1S, Hyp2S and SunS, respectively,
to the PalS S-glycosyltransferase show quite surprisingly that
this similarity is enough to allow modiﬁcation of heterologous
substrates.
The distinctive feature of the glucosylated peptides is a
Cys residue ﬂanked by glycines (Gly-Cys-Gly-Gly/Ser) in the
interhelical loop. PalS, ThuS, and SunS form a sugar S-linkage
with a Cys residue in Gly-Cys-Gly-Gly/Ser motif of interhelical
loop, and this motif is present only in SunA, ThuA, PalA, Hyp1,
and Hyp2. Therefore, we can assign PalA, Hyp1, and Hyp2 to
the sublancin-type glycocins, which is composed of SunA and
ThrA12.
Previous research on the sublancin S-glycosyltransferase, SunS,
suggested that this enzyme recognizes an α-helical segment of the
substrate and glycosylates only a Cys residue in the ﬂexible loop
following this helix48. Studies on thurandacin glycosyltransferase,
ThuS, showed that it glycosylates ThuA at Cys28 or both Ser19
and Cys28. ThuS represents glycosyltransferase that catalyzes
both O- and S-glycosylation of proteins. Earlier studies also
demonstrated that SunS is not able to modify ThuA, although
ThuS is able to modify SunA generating its bisglucosylated pro-
duct. Moreover, SunA and ThuA with changed short sequences in
their interhelical loops were also glucosylated by ThuS in these
regions. On basis of this knowledge, it was suggested that the
peptide sequence selectivity of ThuS is much more relaxed than
that of SunS21. Here, we demonstrate that PalS has quite ﬂexible
substrate selectivity too and that it may monoglycosylate various
precursor peptides: pre-PalA-His, pre-SunA-His, pre-Hyp1-His,
and pre-Hyp2-His. In addition, we show that leaderless Hyp1-His
and Hyp2-His core peptides can be modiﬁed by PalS, resulting in
highly active antibacterial peptide Hyp1-His-Glc but not Hyp2-
His-Glc.
All sublancin-type glycocins, including the pallidocin, Hyp1
and glycosylated core peptide Hyp2, have a relatively rich content
of hydrophobic residues at the N-terminus, and charged residues
at the C-terminus. Comparing the core peptides of glycocins,
Hyp2 has a relatively long C-terminus “tail”, not characteristic to
other sublancin-type glycocins, and is relatively rich in charged
residues (Glu20, Arg21, Arg22) in the interhelical loop (Fig. 2).
These two features or one of them might be the reason why
glycosylated Hyp2 core peptide and precursor did not have
antibacterial activity against the strains tested. This could be the
subject for future research on glycocin variability.
In contrast to previous work on sublancin48, a newly published
study showed that nonglycosylated and oxidatively folded core
peptide of sublancin has the same topology of disulﬁde bonds as
the native sublancin34. In fact, the previous assumptions that the
free thiol of unmodiﬁed Cys disrupts the formation of the correct
disulﬁde bridges by thiol-disulﬁde exchange and the blocked
Cys residue can aid to form correct disulﬁde bonds between four
free Cys residues48 were proven wrong.
We show that the disruption of disulﬁde bonds in the glyco-
sylated precursor peptides pre-PalA-His-Glc, pre-Hyp1-His-Glc
or the PalA-His-Glc and Hyp1-His-Glc core peptides leads to the
loss of antibacterial activity. These data support observations
of earlier investigations on sublancin. It conﬁrms that disulﬁde
bonds are crucial for antibacterial activity of glycocins as well as
glycosylation13,34.
Earlier studies on sublancin and thurandacin showed that the
leader must be cleaved off to gain antibacterial activity13,21. In
contrast, our synthesized glycosylated precursors with leaders
(pre-PalA-His-Glc, pre-SunA-His-Glc and pre-Hyp1-His-Glc)
still showed activity against a sensitive strain, suggesting that the
leader removal from the glycosylated glycocin precursor is not
essential for activity. In fact, glycocins with a leader attached
exhibit substantial antibacterial activity. However, the absence
of the leader increases the activity. It should be noted that in
contrast to previous studies on glycocins, we have used a ther-
mophilic indicator strain, which, as we show, exhibits extreme
susceptibility, even to a leader-containing glycocin.
Previously, only full maturation of recombinant glycocins was
reported in vitro for thurandacin and sublancin. Glycosylation
and leader cleavage was performed enzymatically, followed by
chemical oxidative folding13,21. The in vitro experiments limit the
yield of the end product, are time consuming and expensive.
Recently, a system was developed for the heterologous expression
of sublancin in E. coli SHufﬂe T7 Express cells that in vivo installs
the glycosylation and oxidative folding following a single in vitro
step of proteolytic leader cleavage34. SHufﬂe T7 Express strain
expresses the disulﬁde bond isomerase DsbC, aiding oxidative
folding of proteins in the cytoplasm35. Here, we demonstrate a
different in vivo heterologous expression system for completely
mature glycocins in E. coli BL21(DE3), evading the in vitro
chemical and enzymatic steps.
With the aid of PalS and PalT we can synthesize completely
mature and active pallidocin, which is glycosylated, oxidatively
folded and leaderless. Because pallidocin glycosyltransferase has
ﬂexible substrate selectivity, we propose that PalS could be a good
tool for in vivo biosynthesis and screening of hypothetical gly-
cocins, as we showed with Hyp1 and Hyp2. This approach
demonstrates that after in vivo peptide glycosylation the disulﬁde
bonds most probably are formed spontaneously during the pur-
iﬁcation process. It means that the in vitro chemical oxidative
folding is not absolutely necessary. Moreover, the in vivo glyco-
sylation of core peptides evades the enzymatic leader cleavage.
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Pallidocin exhibits antimicrobial activity against speciﬁc Gram-
positive bacteria. Most of the tested thermophilic bacteria were
susceptible to pallidocin. Among Bacillus sp. only B. megaterium
DSM319 and B. cereus ATCC14579 strains were susceptible. It
indicates a rather narrow activity spectrum restricted to closely
related bacteria. Enterocin F4-9 exhibits antimicrobial activity
against Enterococcus faecalis and E. coli JM10916. Glycocin F has
narrow activity spectrum also that is restricted to the Lactoba-
cillus genus14. Notably, sublancin is active against several Gram-
positive bacteria, like Staphylococcus and, especially Bacillus
species20. Pallidocin MIC values for thermophilic bacteria are
extremely low when compared to the values for B. megaterium
DSM319 and B. cereus ATCC14579. Notably, glycosylated lea-
derless Hyp1 core peptide demonstrated a different activity
spectrum against thermophilic bacteria as compared to pallido-
cin. As in case of sublancin, the susceptible strains relatively easily
develop resistance to pallidocin. The mechanism of resistance
development will be the subject of our future study.
******Studies on sublancin and thurandacin have generally
been focused on in vitro analysis and on the glycosyltransferase as
potential tool for antibody generation and other purposes. S-
linked glycopeptides have been highlighted to be more chemically
and biologically stable compounds than O-linked
glycopeptides13,21. Here, we identiﬁed and characterized anti-
bacterial peptide pallidocin and expanded the currently small
glycocin family. In addition, we demonstrated that glycosyl-
transferase PalS can be used as a tool for the biosynthesis of
glycosylated antibacterial peptides in vivo. We have developed a
system for heterologous expression and screening for hypothetical
sublancin-type precursors with a minimal number of genes
required. Pallidocin or Hyp1 could be applied in industrial pro-
cesses facing thermophilic bacterial contaminations.
Methods
Mass spectrometry analysis. Matrix-assisted laser desorption/ionization time-of-
ﬂight mass spectrometry (MALDI-TOF-MS) analysis was carried out using a
Voyager-DE-Pro (Applied Biosystems) at the Interfaculty Mass Spectrometry
Center (IMSC) of the University Medical Center Groningen (UMCG). One
microliter of analyte was spotted onto an MALDI target and dried under ambient
conditions. One microliter of matrix (saturated α-cyano-4-hydroxy-cinnamic acid
matrix in 50% ACN/50% water with 0.1% TFA) was spotted onto the dried sample
on the MALDI target and dried under ambient conditions prior to analysis. The
Voyager-De-Pro was set in linear positive mode. The spectrum range was
3000–10,000. Voltage settings were 25,000 V acceleration, 93% grid, 0.1% guide
wire. A data Explorer 4.9 (Applied Biosystems) was used to process and analyze the
acquired data.
High-resolution mass spectrometry (LC-ESI-Q-MS and MSMS) was carried out
on a Q Exactive Hybrid Quadrupole-Orbitrap MS system (Thermo Scientiﬁc)
combined with an UltiMate 3000 RSLC system (Thermo Scientiﬁc) at the IMSC of
the UMCG. Each sample was injected into the UltiMate 3000 UHPLC system
consisting of a quaternary pump, an autosampler and a column oven, which was
coupled by a HESI-II electrospray source to the Q Exactive Orbitrap mass
spectrometer (all Thermo Scientiﬁc). A Kinetex EVO-C18 (2.6 µm particles, 100 ×
2.1 mm) column (Phenomenex) was used. The eluents for the LC separation were
(A) water and (B) acetonitrile (ACN) both containing 0.1% formic acid. The
following gradient was used: 5% B until 0.5 min, then linear gradient to 90% B in
4.5 min. This composition was held for 2 min, after which a switch back to 5% B
was performed within 0.1 min. After 2.9 min of equilibration, the next injection
was performed. The LC ﬂow rate was 500 µL/min, the LC column was kept at 60 °C
and the injection volume was 10 µL. The HESI-II electrospray source was operated
with the parameters recommended by the MS software for the LC ﬂow rate used
(spray voltage 3.5 kV (positive mode)); other parameters were sheath gas 50 AU,
auxiliary gas 10 AU, cone gas 2 AU, capillary temperature 275 °C, heater
temperature 400 °C. The samples were measured in positive mode from m/z 500 to
2000 at a resolution of 70,000 @ m/z 200. The instrument was calibrated in positive
mode using the Pierce LTQ Velos ESI Positive Ion Calibration Solution (Thermo
Scientiﬁc). The system was controlled using the software packages Xcalibur 4.1, SII
for Xcalibur 1.3 and Q-Exactive Tune 2.9 (all Thermo Scientiﬁc). The Xtract-
algorithm within Xcalibur was used for deconvolution of the isotopically resolved
data to a monoisotopic spectrum represented in Supplementary Figures 3-9, 16, 17,
21, 26 and 27. For spectra represented in Supplementary Figures 14, 15, 20, and 22-
25, manual deconvolution was calculated by formula 1. Theoretical peptide masses
were calculated using a web tool ProteinProspector (MS-Product/MS-Isotope) at
http://prospector.ucsf.edu/prospector/mshome.htm.
m=z ´ charge mass of the attachedHþð Þ þ 1 ´mass of Hþð Þ
¼ peptidemolecular weight MþH½ þ: ð1Þ
Genomic DNA analysis. The pallidocin producer strain was identiﬁed as Aeri-
bacillus pallidus 8 (previously referred to as Geobacillus sp. 8 32). A Genome-to-
Genome Distance Calculator (GGDC)36,49 for digital DNA−DNA hybridization
(dDDH) analysis at http://ggdc.dsmz.de/home.php was applied for the analysis of
the genome with accession number LVHY00000000.1), which has been sequenced
previously37.
Genomic DNA was submitted for bacteriocin mining to the BAGEL4 server38 at
http://bagel4.molgenrug.nl/. An operon coding for a putative glycocin was
identiﬁed (Fig. 1a) in the genome. The information on the biosynthetic gene cluster
pal, responsible for in vivo production of pallidocin and containing the genes palA,
palS, palT, paldbA, and paldbB, was accessed via the National Center for
Biotechnology Information (NCBI) at http://www.ncbi.nlm.nih.gov/. The gene
cluster is of chromosomal origin with the length of 4805 nucleotides and is found
between base pairs 2768 and 7572 in the contig with accession number
NZ_LVHY01000134.1.
Peptide and protein sequences were submitted to the NCBI database for
BLASTp analysis at https://blast.ncbi.nlm.nih.gov/Blast.cgi. BLASTp analysis
revealed that palA encodes for the 61 amino acid precursor peptide (Fig. 1b) with
39% sequence similarity to the sublancin 168 precursor SunA of B. subtilis
(accession number NP_390031.1). palS encodes for a protein with 53% sequence
similarity to the SunS-like family peptide glycosyltransferase of B. pseudomycoides
(accession number WP_097849814.1). palT encodes for a protein with 38%
sequence similarity to the SunT-like superfamily leader cleavage/ABC-type
transporter of Paeniclostridium sordellii (accession number WP_057576215.1).
paldbA encodes for a protein with 50% sequence similarity to the thioredoxin-like
enzyme of B. megaterium (accession number WP_061859981.1). paldbB encodes a
protein with 47% sequence similarity to the DsbB-like disulﬁde bond formation
protein B of B. cereus (accession number WP_098593227.1).
BLASTp analysis revealed that Hyp1 (accession number WP_061859978.1) is
encoded in the genome of Bacillus megaterium BHG1.1 (accession number
LUCO00000000). The genome encodes the Hyp1 biosynthetic gene cluster, which
is 5013 bp in length and encodes for proteins Hyp1S (accession number
WP_081113339.1), Hyp1T (accession number WP_061859980.1), Trx (accession
number WP_061859981.1), DsbB (accession number WP_061859982.1), and
Hyp1U (accession number WP_061859983.1).
BLASTp analysis revealed that Hyp2 (accession number WP_035395705.1) is
encoded in the genome of Bacillus sp. JCM 19047 (accession number
BAWC00000000). The genome encodes the Hyp2 biosynthetic gene cluster, which
is 3932 bp in length and encodes for proteins: Hyp2T (accession number
WP_035395706.1), Trx (accession number WP_035395707.1), and Hyp2S
(accession number GAF22634.1).
Bacteriocin activity assays. A colony of indicator strain P. genomospecies 1
NUB36187 (BGSC 9A11) was spread on a Nutrient broth (NB) medium agar plate
containing: 1% tryptone (BD Bacto), 0.5% beef extract (BD BBL), 0.5% NaCl
(Merck), 1.5% agar (BD Bacto), and incubated overnight at 60 °C. Grown biomass
was collected with sterile inoculum loop and spread on a fresh NB agar plate and
incubated for 4 h at 60 °C. After the incubation (before cells starts to form spores),
all biomass from the plate was washed with NB medium and the cell suspension
was adjusted to OD (600 nm) of 1. The suspension was mixed with liquid NB agar
medium (55 °C) at the ratio 1:100 and mixed thoroughly. Fifteen milliliters of the
resulting cell suspension was dispersed in a Petri plate and left to solidify. For a well
diffusion assay, wells were cut out in the solid medium in the Petri plate and ﬁlled
with 50 µL of serial twofold dilutions of samples. The titer was deﬁned as the
reciprocal of the highest dilution that resulted in inhibition of the indicator strain.
For a spot on lawn assay, samples of 10 µL were spotted on the solid medium in
the Petri dish and incubated at 60 °C overnight. P. genomospecies 1 NUB36187
(BGSC 9A11) was used as sensitive strain for all experiments. Antibacterial
activities of hypothetical glycocins were tested against other thermophilic and
mesophilic strains by the same approach. When the mesophilic strains were tested
the incubations were performed at 37 °C. Analyzed bacteriocins were screened for
their antibacterial activities against B. cereus ATCC14579, B. megaterium DSM319,
Geobacillus sp. B4113, G. stearothermophilus B4109, B4111, B4112, B4114, B4161,
B4163, P. toebii B4110, B4162, P. caldoxylosilyticus B4119 and C. debilis B4165.
DNA ampliﬁcation by PCR. A single PCR mix included Phusion HF Buffer
(Thermo Scientiﬁc), 2.5 mM dNTPs mix (Thermo Scientiﬁc), 1.5 mM MgCl2
(Thermo Scientiﬁc), PfuX7 DNA polymerase (homemade), primers (0.5 μM each),
and 1 ng/µL DNA template. Target DNA was PCR-ampliﬁed by 30 cycles of
denaturing (94 °C for 30 s), annealing (5 °C or more lower then Tm for 30 s), and
extending (68 °C for 1 min per 1 kbp). Ampliﬁcations were conﬁrmed by 1 or 2%
agarose gel electrophoretic analyses. The list of primers and their sequences is
provided in Supplementary Table 8.
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DNA cloning. DNA digestion was performed with restriction endonucleases
purchased from Thermo Scientiﬁc and according to the manufacturer’s recom-
mendations. Ampliﬁed or digested DNA was always cleaned with a NucleoSpin Gel
and PCR Clean-up Extraction Kit (Macherey−Nagel), unless stated otherwise. A
T4 DNA Ligase (Thermo Scientiﬁc) was used for DNA ligations, according to the
manufacturer’s recommendations, unless stated otherwise. The ligation products
were transformed to E. coli TOP10 cells by electroporation. Cells were plated on
Lysogeny broth (LB) agar plates with appropriate antibiotics and grown at 37 °C
overnight. Several colonies were picked and tested by colony PCR, to conﬁrm
whether the insert is present in the vector. Colonies with correct inserts were
inoculated into LB medium with the appropriate antibiotic. The cultures were
grown at 37 °C overnight, and plasmids were isolated using a NucleoSpin Plasmid
Extraction Kit (Macherey−Nagel). DNA sequences of inserts in isolated plasmids
were always conﬁrmed by DNA sequencing. For gene expression, plasmid DNA
was transformed to E. coli BL21(DE3) by electroporation. Cells were plated on LB
agar plates with appropriate antibiotics and grown at 37 °C overnight. Several
colonies were picked and inoculated into LB medium with the appropriate anti-
biotic, grown overnight at 37 °C, mixed with glycerol (glycerol end concentration
20%) and stored at −80 °C for further use.
Cloning of pallidocin biosynthetic gene cluster pal. A. pallidus 8 was grown in a
Bacto Brain Heart Infusion medium (BD Diagnostics) at 55 °C in a shaking
incubator. Genomic DNAs were extracted with a GenElute Kit (Sigma-Aldrich)
according to the manufacturer’s recommendations. The whole gene cluster pal
encoding the pallidocin biosynthetic machinery (Fig. 1a) was ampliﬁed by PCR as a
single unit (4805 bp) using F-PalA-USER and R-PalA-USER primers and A. pal-
lidus 8 genomic DNA as template. The pBAD24 vector was PCR-ampliﬁed using F-
pBAD-USER and R-pBAD-USER primers and pBAD24 plasmid as the template.
Obtained PCR products were ligated by USER Enzyme (NEB), according to the
manufacturer’s protocol, and transformed to E. coli TOP10 cells by electroporation.
Colony PCR method using F-pBAD24 and R-pBAD24 primers was used for
selection of positive transformants. Obtained construct pBAD24-pal was propa-
gated in E. coli TOP10 cells and isolated. The presence of the cloned insert in the
construct was conﬁrmed by PCR (Supplementary Fig. 1). To amplify the insert the
following pairs of primers were used together with pBAD24-pal as the template:
the whole gene cluster pal (F-PalA-BspHI and R-BdbB); palA (F-PalA-BspHI and
R-PalA-HindIII); palS (F-PalS-In-Fusion and R-PalS-In-Fusion); palT (F-PalT-In-
Fusion and R-PalT-In-Fusion); bdbA (F-BdbA and R-BdbA); bdbB (F-BdbB and
R-BdbB).
The sequence of the insert (pal gene cluster) was conﬁrmed by DNA
sequencing. DNA sequencing was performed with primers: F-pBAD24, R-pBAD24,
Pal0, Pal1, Pal2, Pal3, Pal4, Pal5, and Pal6. The insert pal, starting with the start
codon for the PalA, was cloned into the MCS behind the arabinose promoter and
RBS of the pBAD24 vector. Sequences of primers are provided in Supplementary
Table 8. For the protein expression pBAD24-pal was transformed to E. coli
BL21(DE3).
Overexpression of pal and puriﬁcation of pallidocin. E. coli BL21(DE3) cells
transformed with pBAD24-pal was grown overnight at 37 °C in LB medium
containing ampicillin (50 µg/mL) and inoculated to 1 L of M9-ampicillin minimal
medium (12.8 g/L Na2HPO4 × 7H2O, 3 g/L KH2PO4, 0.5 g/L NaCl, 1 g/L NH4Cl,
0.24 g/L MgSO4, 0.11 g/L CaCl2, and 4 mL glycerol in MiliQ water) at the ratio
1:100. The cells were grown at 37 °C to the OD (600 nm) of 0.6–0.7, then arabinose
was added to the ﬁnal concentration of 2 mM and the culture was incubated at 37 °
C for additional 16 h. Cells were harvested by centrifugation at 10,000 × g for 15
min at 4 °C. Supernatant was collected, immediately ﬁltered through a 0.45 µm
ﬁlter and uploaded on an Econo-Column chromatography column, 2.5 × 30 cm
(Bio-Rad) ﬁlled with a 50 g of Amberlite XAD16N hydrophobic polyaromatic resin
(Sigma-Aldrich), which was previously equilibrated with deionized water. After
sample loading, the column was washed with 500 mL deionized water. Elution was
performed with 250 mL of 100% methanol. The eluate was collected, diluted with
deionized water (ratio 1:3) and lyophilized in a freeze-dryer. Pellets were dissolved
in 100 mL of 50 mM lactic acid buffer (pH 4.5) and ﬁltered through a 0.45 µm ﬁlter.
Then, it was loaded on an NGC system (Bio-Rad) equipped with a HiTrap SP HP
5mL cation exchange column (GE Healthcare Life Sciences), which was previously
equilibrated with 50 mM lactic acid buffer (pH 4.5). The column was then washed
with 50 mM lactic acid buffer (pH 4.5) and elution performed with 50 mM lactic
acid buffer containing 300 mM NaCl (pH 4.5). The eluate was mixed with
triﬂuoroacetic acid (TFA) to the end concentration of 0.1% and loaded on an RP-
HPLC system (Agilent) equipped with a Jupiter Proteo, C-12, 250 × 10 mm column
(Phenomenex). The column was equilibrated in 5% of solvent B (solvent A=
MiliQ water with 0.1% TFA, solvent B=ACN with 0.1% TFA). Bacteriocin was
eluted by an increase of solvent B up to 60% over 80 min with a ﬂow rate of 2 mL/
min. Elution fractions were tested for antibacterial activity against P. genomospecies
1 NUB36187 using a drop on a lawn assay. Active fractions were lyophilized, pellets
dissolved in a solution containing 6M guanidine-HCl and 0.1% TFA, and applied
on a Jupiter Proteo, C-12, 250 × 4.6 mm column (Phenomenex) which was equi-
librated in 5% of solvent B. Bacteriocin was eluted by an increase of solvent B up to
60% over 80 min with a ﬂow rate of 1 mL/min. Elution fractions were tested for
antibacterial activity against P. genomospecies 1 NUB36187 using a spot on lawn
assay. Samples of elution fractions with antibacterial activity were analyzed by
MALDI-TOF-MS, and the rest were lyophilized and stored at −80 °C until
further use.
Cloning for gene coexpression. The gene palA was ampliﬁed by PCR using
F-PalA-BspHI and R-PalA-HindIII primers, the gene palS was ampliﬁed by PCR
using F-PalS-In-Fusion and R-PalS-In-Fusion primers. The gene palT was ampli-
ﬁed by PCR using F-PalT-In-Fusion and R-PalT-In-Fusion primers. The DNA
region containing two genes palS and palT was ampliﬁed by PCR using F-PalS-In-
Fusion and R-PalT-In-Fusion primers. A. pallidus 8 genomic DNA was used as
the template to amplify the genes.
Ampliﬁed palA was double digested with BspHI and HindIII. pRSFDuet-1
vector was double digested with NcoI and HindIII. Both digestion products were
cleaned and ligated by a conventional cloning. The ligation mixtures were
transformed to E. coli TOP10 cells by electroporation. Positive colonies were
selected by colony PCR using F-pRSFDuet-1 and R-pRSFDuet-1 primers. Positive
clones were propagated for the plasmid isolation. The sequences of the inserts
in the constructs were conﬁrmed by DNA sequencing using F-pRSFDuet-1 and
R-pRSFDuet-1 primers.
A site-directed mutagenesis approach was used to introduce the His7-tag
sequence (GGHHHHHHH) in the C-terminus of the PalA peptide. A new
construct pRSFDuet-1 encoding palA-his was generated by PCR ampliﬁcation
using 5′-phosphorylated primers F-PalA-His and R-PalA-His. Construct
pRSFDuet-1-palA was used as template. The PCR product was cleaned, ligated and
transformed to E. coli TOP10. Positive clones were conﬁrmed by colony PCR
and propagated for plasmid isolation. The His7-tag encoding sequence in the
resulting construct (pRSFDuet-1-palA-his) was conﬁrmed by DNA sequencing
using F-pRSFDuet-1 and R-pRSFDuet-1 primers.
To introduce a Factor Xa cleavage site and a His-tag (N-terminus) in the PalA
peptide, a his-Xa-palA gene was engineered. First, the gene palA was ampliﬁed by
PCR using F-PalA-BamHI and R-PalA-HindIII2 primers and A. pallidus 8 genomic
DNA as the template. PCR product palA and vector pRSFDuet-1 were double
digested with BamHI and HindIII according to the manufacturer’s
recommendations. Resulting products were cleaned, ligated by conventional
cloning and transformed to E. coli TOP10 by electroporation. Positive clones were
selected by colony PCR using F-pRSFDuet-1 and R-pRSFDuet-1 primers and
propagated for isolation of plasmids. The sequence of the insert was conﬁrmed by
DNA sequencing using F-pRSFDuet-1 and R-pRSFDuet-1 primers. The insert,
palA gene, in the resulting construct pRSFDuet-1-his-palA was introduced behind
the His6-tag encoding sequence (MGSSHHHHHHSQDP).
Next, a site-directed mutagenesis approach was used to incorporate a Factor Xa
proteolytic cleavage site to the N-terminal part of the PalA peptide (Supplementary
Fig. 13). Four wild-type peptide residues LQGS were changed to IEGR. pRSFDuet-
1 coding for his-Xa-palA was ampliﬁed by PCR using 5′-phosphorylated primers
F-PalA-Xa and R-PalA-Xa and template pRSFDuet-1-his-palA, then ligated and
transformed to E. coli TOP10 by electroporation. Positive clones were selected by
colony PCR followed by plasmid isolations. Correct sequence of constructed
pRSFDuet-1-his-Xa-palA vector was conﬁrmed by DNA sequencing using F-
pRSFDuet-1 and R-pRSFDuet-1 primers. Sequences of the primers are provided
in Supplementary Table 8.
Synthetic genes of sublancin 168 (sunA-his), glycocin F (gccF-his), enterocin
F4-9 (enfA4-9-his), hypothetical peptide 1 (hyp1-his), and hypothetical peptide 2
(hyp2-his) were synthesized by GenScript with codon optimization for E. coli and
delivered in a pUC57 vector. The genes encode glycocin precursors with leaders
and His6-tag sequences (HHHHHH) in the C-terminuses of the peptides. All
synthesized genes were cloned into the pRSFDuet-1 vector and transformed to
E. coli TOP10. The presences of the inserts in the vector pRSFDuet-1 were
conﬁrmed by PCR (Supplementary Fig. 19). To amplify the inserts, the following
primer pairs were used: sunA-his (primers F-SunA-BamHI and R-SunA-HindIII);
hyp1-his (primers F-Hyp1 and R-Hyp1); hyp2-his (primers F-Hyp2 and R-Hyp2);
gccF-his (primers F-GccF and R-GccF); enfA4-9-his (primers F-EnfA4-9 and R-
EnfA4-9). Constructed pRSFDuet-1 vectors coding for the cloned genes were used
as the templates, respectively. Sequences of the inserts in the plasmids were also
conﬁrmed by DNA sequencing using F-pRSFDuet-1 and R-pRSFDuet-1 primers.
Sequences of the primers are provided in Supplementary Table 8.
A site-directed mutagenesis approach was used to engineer core_hyp1-his and
core_hyp2-his genes coding for Hyp1-His and Hyp2-His core peptides without
leader sequences and with a His6-tag (HHHHHH) in the C-terminuses
(Supplementary Fig. 13). pRSFDuet-1-core_hyp1-his was ampliﬁed by PCR using
5′-phosphorylated primers F-Hyp1-Leaderless and R-Leaderless. pRSFDuet-1-
core_hyp2-his was ampliﬁed by 5′-phosphorylated primers F-Hyp2-Leaderless and
R-Leaderless. pRSFDuet-1-hyp1-his and pRSFDuet-1-hyp2-his vectors were used
as templates, respectively. Obtained PCR products were ligated and transformed to
E. coli TOP10 by electroporation. Positive clones were selected by colony PCR
using F-pRSFDuet-1 and R-pRSFDuet-1 primers and propagated for isolation of
plasmids. The presences of the genes coding for leaderless peptides in the vectors
were conﬁrmed by PCR (Supplementary Fig. 19). We ampliﬁed the insert
core_hyp1-his by primers F-Hyp1-Leaderless and R-Hyp1-HindIII, and pRSFDuet-
1-core_hyp1-his vector as template. The insert core_hyp2-his was ampliﬁed by
primers F-Hyp2-Leaderless and R-Hyp2, and pRSFDuet-1-core_hyp2-his vector as
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template. In addition, the inserts encoding Hyp1-His and Hyp2-His core peptides
were conﬁrmed by DNA sequencing using F-pRSFDuet-1 and R-pRSFDuet-1
primers. Sequences of the primers are provided in Supplementary Table 8.
To generate pBAD24 vectors coding for genes palS, palT and palST, the
pBAD24 vector was double digested with NcoI and PstI, separated by DNA
electrophoresis and extracted from agarose gel using a NucleoSpin Gel and PCR
Clean-up Extraction Kit (Macherey−Nagel). Next, PCR-ampliﬁed palS, palT and
palST were ligated with the double digested pBAD24 vector using a Quick-Fusion
Cloning Kit (Bimake) according to the manufacturer’s recommendations. After
the ligation, the mixtures were diluted with MiliQ in ratio 1:5 and transformed
to E. coli TOP10 by electroporation. Positive clones were selected by colony PCR
using F-pBAD24 and R-pBAD24 primers and propagated for isolation of plasmids.
The presences of the cloned inserts in the constructs were conﬁrmed by PCR
(Supplementary Fig. 12). We ampliﬁed the insert palA-his by primers F-PalA-
BspHI and R-PalA-HindIII, and pRSFDuet-1-palA-his vector as template. The
insert palS was ampliﬁed by primers F-PalS-In-Fusion and R-PalS-In-Fusion, and
pBAD24-palS vector as template. The insert palT was ampliﬁed by primers F-PalT-
In-Fusion and R-PalT-In-Fusion, and pBAD24-palT vector as template. The insert
palST was ampliﬁed by primers F-PalS-In-Fusion and R-PalT-In-Fusion, and
pBAD24-palST vector as template.
Sequences of the inserts in the resulting constructs (pBAD24-palS, pBAD24-
palT and pBAD24-palST) were also conﬁrmed by DNA sequencing. We used F-
pBAD24, R-pBAD24, and Pal1 primers for pBAD24-palS sequencing; F-pBAD24,
R-pBAD24, Pal3, Pal4, and Pal5 primers for pBAD24-palT sequencing; F-pBAD24,
R-pBAD24, Pal1, Pal2, Pal3, Pal4, and Pal5 primers for pBAD24-palST sequencing.
Genes of precursors were cloned in MCS1 behind the IPTG promoter and
RBS of the pRSFDuet-1 vector. Genes palS/palT/palST were cloned into the MCS
behind the arabinose promoter and RBS of the pBAD24 vector. Sequences of
primers are provided in Supplementary Table 8. The vectors pRSFDuet-1 and
pBAD24 coding for palS/palT/palST were transformed to E. coli BL21(DE3) for
protein expression experiments.
Coexpression of glycocin precursors with PalS and PalT. E. coli BL21(DE3)-
containing vectors pRSFDuet-1-palA-his and pBAD24 coding for either palS, palT
or palST were grown at 37 °C overnight in LB medium containing ampicillin (50
µg/mL) and kanamycin (30 µg/mL). The next day it was inoculated into 100 mL
of fresh LB−ampicillin−kanamycin medium in the ratio 1:100 and grown at 37 °C
to the OD (600 nm) of 0.6−0.7. Arabinose and IPTG were added to a ﬁnal con-
centration of 1 mM of each and the culture was grown for additional 4 h at 37 °C.
After the induction, cells were harvested by centrifugation at 7000 × g for 15 min
at 4 °C and resuspended in 5 mL of binding buffer (20 mM NaH2PO4, 500 mM
NaCl, pH 7.4).
pRSFDuet-1 vectors with cloned glycocin precursor genes: sunA-his/gccF-his/
enfA4-9-his/hyp1-his/hyp2-his, were coexpressed in E. coli BL21(DE3) together with
the pBAD24 vector coding for palS/palT/palST, respectively. The pRSFDuet-1
vector coding for his-Xa-palA was coexpressed in E. coli BL21(DE3) together with
the pBAD24 vector coding for palS. The coexpression was performed in the
same approach as the coexpression of pRSFDuet-1-palA-his with pBAD24-pasS.
pRSFDuet-1 vector encoding core_hyp1-his/core_hyp2-his was coexpressed with
pBAD24 vector encoding palS in E. coli BL21(DE3). The coexpression was induced
for 7 h by the same approach as was coexpression of pRSFDuet-1-palA-his with
pBAD24-pasS.
Puriﬁcation of the peptides. The obtained cell suspension after coexpression was
sonicated on ice for 20 min using a VCX 130 Sonicator with cycle 10 s ON and 10 s
OFF. The highest concentration of the produced peptide was found in the insoluble
fraction of lysed cells. Cell debris was removed by centrifugation at 15,000 × g for
20 min at 4 °C. The supernatant was discarded and the pellet of insoluble fraction
was resuspended and sonicated at the same conditions in 5 mL of binding buffer
containing 6M guanidine-HCl. The sample was ﬁltered through a 0.45 μm ﬁlter
and applied to an NGC system (Bio-Rad) equipped with a HisTrap FF 1 mL
(GE Healthcare Life Sciences) immobilized metal afﬁnity chromatography (IMAC)
column pre-equilibrated with binding buffer containing 4M guanidine-HCl. After
sample application, the column was washed with binding buffer containing 4M
guanidine-HCl. The peptide was eluted with elution buffer (20 mM NaH2PO4, 500
mM NaCl, 500 mM imidazole, pH 7.4) containing 4M guanidine-HCl.
The fractions containing eluted peptides were further puriﬁed by an RP-HPLC
system (Agilent) equipped with Jupiter Proteo, C-12, 250 × 10 mm column
(Phenomenex). The eluate was mixed with TFA to reduce the pH to 2–3 and
loaded on the column equilibrated in 5% of solvent B. The peptides were eluted
by an increase of solvent B up to 60% over 60 min with a ﬂow rate of 2 mL/min. All
fractions were tested for antibacterial activity against P. genomospecies 1 NUB36187
using a drop on lawn assay. Additionally, elution fractions were analyzed by
MALDI-TOF-MS and LC-ESI-MS.
Leader cleavage of the pre-His-Xa-PalA-Glc peptide. Lyophilized pellets of
puriﬁed glycosylated pallidocin precursor pre-His-Xa-PalA-Glc were dissolved in
1 mL of 6M guanidine-HCl and loaded on gel ﬁltration column PD-10 (GE
Healthcare Life Sciences). The buffer exchange of the sample was performed
according to the manufacturer’s recommendations. The column was pre-
equilibrated with 50 mM tris-HCl, 100 mM NaCl, pH 7.5 buffer. The eluate was
collected and mixed with CaCl2 to the end concentration of 2 mM. 10–20 µL of
Factor Xa peptidase (enzyme concentration 1 mg/mL, NEB) was added to 0.5 mL
of previously gel ﬁltrated peptide solution (peptide concentration 0.5 mg/mL). The
mixture was stored at room temperature for 3–6 h. After sample treatment with the
peptidase, 4 mL of 6 M guanidine-HC and TFA, to quench the pH to 2–3, were
added. Then, the sample was loaded on an RP-HPLC system (Agilent) equipped
with a Jupiter Proteo, C-12, 250 × 4.6 mm column (Phenomenex) equilibrated in
5% of solvent B. The peptide was eluted by an increase of solvent B from 20% up to
60% over 80 min with a ﬂow rate of 1 mL/min. Elution fractions were tested for
antibacterial activity against P. genomospecies 1 NUB36187 using a drop on lawn
assay. The elution fractions were analyzed by MALDI-TOF-MS. Elution fractions
containing active and glycosylated pallidocin core peptide PalA-Glc were lyophi-
lized by freeze-dryer. Pellets were stored at −20 °C or dissolved in MiliQ con-
taining 50% ACN and 0.1% TFA solution for further use. The quantity of puriﬁed
peptide was measured by a NanoPhotometer N60 (Implen). The molar absorptivity
(extinction coefﬁcient) was calculated (at 280 nm and 13,200/M/cm or at 205 nm
and 171,330/M/cm) based on the peptide sequence. Calculations were performed
by a web tool, provided at http://spin.niddk.nih.gov/clore48. Determined peptide
quantities at 280 and 205 nm were the same. The yield of synthesized pallidocin
from 200 mL of bacterial culture was ~30 µg.
Iodoacetamide assays for detection of free cysteines. To detect the presence of
free cysteine thiols in peptides, an iodoacetamide (IAA) assay was used. For the
detection of free Cys residues in the native peptide, reactions contained 100 mM
tris-HCl (pH 8.3), 40 mM IAA and the peptide. For the detection of free Cys
residues in a reduced peptide, reactions contained 100 mM tris-HCl (pH 8.3),
10 mM TCEP, 40 mM IAA and the peptide. All reactions were in total volume of
1 mL, incubation conditions were 2 h at room temperature in the dark. The
reaction mixtures were quenched with TFA to pH < 4. Samples were loaded on an
RP-HPLC system (Agilent) equipped with a Jupiter Proteo, C-12, 250 × 4.6 mm
column (Phenomenex) equilibrated in 5% of solvent B. Peptides were eluted by
an increase of solvent B from 20% up to 60% over 40 min with a ﬂow rate of
1 mL/min. Elution fractions containing peptides were tested for antibacterial
activity against P. genomospecies 1 NUB36187 using a drop on lawn assay and
further analyzed by MALDI-TOF-MS. The detection of free cysteines was deter-
mined by the presence or absence of thiol modiﬁcations, carboxyamidomethyl
(CAM).
Effects of pH on bacteriocin stability. 50 mM buffer solutions of KCl-HCl pH 2,
citric acid-sodium citrate pH 4, phosphate pH 6, tris-HCl pH 8 and sodium
carbonate-sodium bicarbonate pH 10 were prepared for the following assay.
Pallidocin was dissolved in MiliQ water containing 50% ACN and 0.1% TFA to the
end concentration of 1 ng/µL. 13.5 µL of each buffer solution was mixed with 1.5 µL
of pallidocin solution and the resulting mixtures were stored for 3 h at room
temperature. After the incubation, 15 µL of 500 mM tris-HCl pH 7.5 buffer
solution and 120 µL of NB medium were added to the mixtures. Next, serial
twofold dilutions with NB medium were made for each mixture. Bacteriocin
activity was tested for each sample with agar well diffusion assay.
Effect of temperature on bacteriocin stability. Pallidocin was dissolved in MiliQ
water containing 50% ACN and 0.1% TFA to the end concentration of 1 ng/µL.
One hundred and ﬁfty microliters of NB medium was mixed with 1.5 µL pallidocin
solution and stored at room temperature for 24 h, 10 days and 30 days. In addition,
samples were stored at different temperatures: 60 °C, 90 °C for 3 h and autoclaved
for 15 min at 121 °C. After the incubation, serial twofold dilutions in NB medium
were made for each mixture. Bacteriocin activity was tested for each sample with
agar well diffusion assay.
Determination of minimum inhibitory concentrations. MICs were determined as
described by Wiegand et al.50 with some modiﬁcations. One colony of a sensitive
strain was picked from an NB agar plate, inoculated to liquid NB medium and
grown at 55 °C, in a shaking incubator until OD (600 nm) of 0.1 was reached.
Then, the culture was diluted with NB medium till concentration of 10×105 CFU/
mL. One hundred and ﬁfty microliters of fresh NB medium was mixed with 5 µL of
pallidocin solution (1 ng/µL in 50% ACN and 0.1% TFA) and serial twofold
dilutions with NB medium were made. Seventy-ﬁve microliters of resulting diluted
pallidocin mixtures were transferred to a 96-well plate and mixed with 75 µL
previously prepared cell suspension of sensitive strain. The ﬁnal volume of the
mixture in the well was 150 µL and the end concentration of the sensitive strain was
5×105 CFU/mL. Positive controls, 150 µL mixture of NB medium with the sensitive
strain (5×105 CFU/mL), and negative controls, 150 µL mixture of NB medium with
5 µL of pallidocin solution (1 ng/µL in 50% ACN and 0.1% TFA), were prepared
and dispersed in the same 96-well plates. The plate with a lid was placed in a plastic
box (12 cm × 20 cm × 6 cm) with a wet paper towel to keep high humidity and
prevent medium evaporation at high temperature. The plate was incubated for 18 h
at 55 °C in a shaking incubator. After incubation the growth of bacteria was
evaluated visually and by a plate reader. The analyses were performed in triplicate.
It should be noted that because of the high mutation rate and emergence of
resistant mutants in some wells in the plate, the calculation of average MIC from
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three replicates are prone to variation. The ﬁnal MIC value was determined by the
lowest amount of pallidocin required to inhibit cell growth in a well. Because
bacteria were grown at 55 °C, it was not possible to use a plate reader at this
condition, as the instrument is not suited for measurements at high temperatures.
Determination of the sugar modiﬁcation of pallidocin. The presence of a sugar
moiety on Cys25 of pallidocin core peptide was conﬁrmed via acid-catalyzed
methanolysis and derivatization of the sugar, analysis by gas chromatography-mass
spectrometry (GC-MS), and comparison to derivatized sugar standards. Puriﬁed
pallidocin was lyophilized in a glass tube, internal standard-mannitol and 0.5 mL of
methanolic 1 M HCl (Sigma-Aldrich) were added. The mixture was heated at 85 °C
overnight. The reaction was cooled at room temperature and neutralized by adding
solid Silver Carbonate (Sigma-Aldrich) till pH 7. For re-N-acetylation, two drops of
Acetic Anhydride (Sigma-Aldrich) was added, mixed and stored overnight at room
temperature in the dark. Next day, the reaction mixture was centrifuged at 1000 × g
for 2 min. Supernatant was transferred to a new glass tube. 0.5 mL of methanol
was added to the silver salt pellets, mixed and centrifuged again. Supernatant
was collected and pooled with the ﬁrst one. The procedure was repeated twice.
Collected supernatant was evaporated in a vacuum evaporator. Tri-methylation of
the sugar was performed by adding 0.3 mL of silylation reagents (pyridine:hex-
amethyldisilazane:trimethyl-chlorosilane= 5:1:1). The mixture was incubated at
room temperature for 30 min.
Sugar standards mix: D-mannose, D-galactose, D-glucose, N-acetylgalactosamine
and N-acetylglucosamine were also treated and derivatized using the conditions
described above.
The derivatized sugar of pallidocin and sugar standards mix were analyzed
individually by a GCMS-QP2010 Plus system (Shimadzu) equipped with a Zebron
ZB-1HT column, L= 30 m × I.D.= 0.25 mm × df= 0.25 μm (Phenomenex). The
temperature gradient was from 140 to 240 °C at 4 °C per min. The carrier gas was
helium and the ﬂow rate set at 2.0 mL/min.
Circular dichroism spectroscopy. Circular dichroism (CD) spectra were recorded
using a J-815 CD Spectrometer (JASCO) with a cuvette of 0.1 cm path length in the
range from 190 to 260 nm at 0.5 nm intervals. For CD spectrum measurement
lyophilized pallidocin was dissolved in a solvent (40% ACN, 0.1% TFA) to a ﬁnal
concentration of 9 µM. The spectrum of scan was obtained with a 2 nm optical
bandwidth. The baseline scans were collected with the solvent alone and then
subtracted from the sample scan. The estimate of secondary structure content was
made using spectra from 193 nm to 260 nm by the method of Raussens et al.42
at http://perry.freeshell.org/raussens.html.
Code availability. The BAGEL438 server (http://bagel4.molgenrug.nl/) was used
for bacteriocin mining in the genome sequences. The strain was identiﬁed by
submitting its genomic DNA sequence to a Genome-to-Genome Digital Calculator
(GGDC)36,49 for digital DNA−DNA hybridization (dDDH) analysis at http://ggdc.
dsmz.de/home.php. BLAST analyses of peptide and protein sequences were
performed using the NCBI database at https://blast.ncbi.nlm.nih.gov/Blast.cgi.
Calculations of extinction coefﬁcients for peptide’s absorbance at 280 and
205 nm were performed by a web tool Protein Calculator51 at http://spin.niddk.nih.
gov/clore. Theoretical peptide mass calculations were performed using a web
tool ProteinProspector (MS-Product/MS-Isotope) at http://prospector.ucsf.edu/
prospector/mshome.htm. The estimate of secondary structure content based on
far-UV CD spectroscopy was made by the method of Raussens et al.42 at http://
perry.freeshell.org/raussens.html. The estimate and modeling of secondary
structures based on amino acid sequences were made by PSIPRED22 web tool at
http://bioinf.cs.ucl.ac.uk/psipred/.
Reporting summary. Further information on experimental design is available
in the Nature Research Reporting Summary linked to this article.
Data availability
Data supporting the ﬁndings of this work are available within the paper and
its Supplementary Information ﬁles. A reporting summary for this article is available as
a Supplementary Information ﬁle. The source data underlying Supplementary Figures 1,
11, 12, 19 and Supplementary Tables 5−7 are provided as a Source Data ﬁle. All other
data are available from the corresponding author on request.
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